ストックスクリーナーアプリを入手
49.48
0.37%
0.18
アフターアワーズ：
49.48
前日終値:
$49.30
開ける：
$49.59
24時間の取引高:
4.26M
Relative Volume:
1.23
時価総額：
$21.99B
収益：
$2.38B
当期純損益:
$1.32B
株価収益率:
27.79
EPS:
1.7806
ネットキャッシュフロー:
$897.24M
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
+9.08%
6か月 パフォーマンス:
+32.02%
1年 パフォーマンス:
+53.71%
1日の値動き範囲:
$48.88
$49.80
1週間の範囲:
$48.08
$50.08
52週間の値動き範囲:
$31.58
$50.08
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
49.48 | 21.91B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 51.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.49B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 35.31B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation - The Manila Times
A new $1 million prize will honor scientists who turn discoveries into drugs - Stock Titan
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS raises Royalty Pharma stock price target on biopharma catalysts By Investing.com - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $57 at UBS - StreetInsider
Royalty Pharma Approves Dividend and Expands J&J Research Funding - HarianBasis.co
Royalty Pharma declares $0.235 dividend - MSN
Royalty Pharma Plc Hits New 52-Week High of USD 50.00 - Markets Mojo
Royalty Pharma Plc (RPRX): Investor Outlook With A Promising 3.56% Potential Upside - DirectorsTalk Interviews
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now - Yahoo Finance
Moran Wealth Management LLC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
KBC Group NV Trims Holdings in Royalty Pharma PLC $RPRX - MarketBeat
5 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com India
Royalty Pharma PLC (NASDAQ:RPRX) Declares $0.24 Quarterly Dividend - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $49.07 By Investing.com - Investing.com Canada
Royalty Pharma stock hits 52-week high at $49.07 - Investing.com
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026 - marketscreener.com
Royalty Pharma declares $0.235 quarterly dividend - Investing.com
Royalty Pharma Keeps Quarterly Dividend at $0.235 per Share, Payable June 10 to Shareholders of Record as of May 15 - marketscreener.com
Royalty Pharma Declares Second Quarter 2026 Dividend - The Manila Times
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.9% Yield - StreetInsider
Royalty Pharma will pay shareholders 23.5 cents a share on June 10 - Stock Titan
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 166,403 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Announce Q1 2026 Results on May 6 - National Today
TD Cowen lifts PT on Royalty Pharma plc (RPRX) to $50 from $45, here’s why - MSN
Royalty Pharma : Q1 2026 Pre-Quarterly Results Communication - marketscreener.com
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 - The Manila Times
Royalty Pharma schedules May 6 results, 8 a.m. investor webcast - Stock Titan
Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : 2025 Corporate Responsibility Report pdf - marketscreener.com
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Robeco Institutional Asset Management B.V. Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc 8-K Filing – April 2026 Company Information and SEC Disclosure - Minichart
Royalty Pharma funds additional $250M after Phase 3 win for daraxonrasib in metastatic PDAC - TradingView
Royalty Pharma (NASDAQ: RPRX) deepens $2B daraxonrasib royalty and loan pact - Stock Titan
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6% - Insider Monkey
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Technical Reactions to RPRX Trends in Macro Strategies - Stock Traders Daily
Trend Review: Does Royalty Pharma plc have high return on assetsForecast Cut & Fast Exit and Entry Trade Guides - baoquankhu1.vn
[ARS] Royalty Pharma plc SEC Filing - Stock Titan
[DEF 14A] Royalty Pharma plc Definitive Proxy Statement - Stock Titan
Today's Analyst Rating Update for Royalty Pharma (RPRX) | RPRX S - GuruFocus
Assessing Royalty Pharma (RPRX) Valuation After Johnson & Johnson Autoimmune Co Funding Deal - Sahm
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest - Yahoo Finance
Does J&J Co-Funding Deal Around Dual-Pathway Autoimmune Candidate Recast The Bull Case For Royalty Pharma (RPRX)? - Sahm
Volume Summary: Can Royalty Pharma plc scale operations efficiently2026 Highlights & Capital Protection Trading Alerts - baoquankhu1.vn
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.66%
6.09%
大文字化:
|
ボリューム (24 時間):